Before obtaining consent for the Meningococcal ACWY vaccine for the Targeted Regional WA MenW Outbreak Response, provide the information sheet on the back of this page is to be used to explain the vaccine as part of the consent, and the checklist should be used to screen each person receiving the vaccine.

Region:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Community:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Check List Prior to vaccination:**

* Check vaccination history on AIR. NB if previously given Menitorix® vaccine there should be a 4 week interval before giving Menveo® or NIMENRIX®.
* Check which vaccine to use: Menveo for children less than 12 months (or if completing a course of Menveo). NIMENRIX for all people 12 months and older. Refer to the October 2017 Meningococcal Dosage Schedule.

**Is the person receiving the vaccine:**

* unwell today with a fever >38 degrees
* **ALLERGIC** to any component of the vaccine or history of reaction to vaccinations
* has a chronic illness (discuss with nurse as may need additional doses)
* has a bleeding disorder: may develop haematomas at IM injection site
* Pregnant:

Use in Pregnancy and Breastfeeding. There is limited experience using MenACWY vaccines in pregnant women. Studies in animals with NIMENRIX brand MenACWY vaccine do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development. Still, MenACWY vaccines should be used during pregnancy only when clearly needed, i.e. if the patient is thought to be at increased risk of meningococcal disease, such as living in the communities that are part of the Targeted Regional WA MenW Outbreak Response, and the possible advantages outweigh the potential risks for the foetus. Breast feeding women can be offered the vaccination.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **House Number (or community if from another community)** | **Last name** | **First name** | **DOB**  **(Age if DOB unknown)** | **ATSI/Non-ATSI** | **Menveo (2 months to 11 months of age)**  **Batch No.** | **Nimenrix**  **12 months and older (unless Menveo given as previous doses)**  **Batch No.** | **Consent obtained (tick or sign)** | **Initial of Immuniser** | **Date Given** |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

**Why is the Targeted Men W program happening, and who is it for?**

This program is being offered in in response to the Meningococcal W outbreak in the Northern Territory and South Australia. To protect the communities close to the state borders of the Northern Territory and South Australia and slow or stop the spread of the outbreak, vaccination is being offered to ***every person over the age of 2 months,*** that lives in the following remote communities: Ngaanyatjarra Lands and Tjuntjuntjara (Goldfields); Balgo, Bililuna, Mulan and Kundat Jaru/Ringer Soak (Kimberley); and Punmu, Kunawarritji, Jigalong and Parnngurr/Cotton Creek (Pilbara).

**What vaccines are being used, and how safe are they?**

The vaccines being used are Meningococcal vaccines called Menveo and NIMENRIX. Both vaccines cover the A, C, W and Y strains of Meningococcal. Menveo is used for all children under the age of 1 year, and multiple doses of the vaccine will be needed. NIMENRIX is used for every person over the age of 1 years old, and just 1 dose is needed. Both Menveo and NIMENRIX are considered safe and well tolerated. However, all medicines can have side effects. These are usually mild and go away by themselves. Serious side effects are possible, but are rare. Some common side effects of the MenW vaccines can be:

Tell the client: If you or your child has a bad side effect after having this vaccine, you should go immediately to your community clinic and see your nurse or Doctor.

Clinicians and consumers can also report a bad side effect on the Western Australian Vaccination Safety Surveillance (WAVSS) system at [www.wavss.health.wa.gov.au](http://www.wavss.health.wa.gov.au) (24 hours a day, 7 days a week)

* Pain and swelling at injection site
* Headache
* Nausea or stomach pains
* Muscle or joint pain
* Rash

**The following pre-vaccination checklist must be used to consent each individual person receiving vaccine. The Public Health Unit is available for further advice, contact details at** [**http://www.healthywa.wa.gov.au/publichealthunits**](http://www.healthywa.wa.gov.au/publichealthunits)**. Is the person receiving the vaccine:**

* unwell today with a fever >38 degrees
* **Allergic** to any component of the vaccine or history of reaction to vaccinations
* has a chronic illness (discuss with nurse as may need additional doses)
* has a bleeding disorder: may develop haematomas at IM injection site
* Pregnant: Use in Pregnancy and Breastfeeding. There is limited experience using MenACWY vaccines in pregnant women. Studies in animals with NIMENRIX brand MenACWY vaccine do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development. Still, MenACWY vaccines should be used during pregnancy only when clearly needed, i.e. if the patient is thought to be at increased risk of meningococcal disease, such as living in the communities that are part of the Targeted Regional WA MenW Outbreak Response, and the possible advantages outweigh the potential risks for the foetus. Breast feeding women can be offered the vaccination.

**Once each person has been informed of the reason for the program, the vaccine safety and side effects, and has had their pre-vaccination checklist done, they can consent for the vaccine.**